Roguljic, H., Nincevic, V., Bojanic, K., Kuna, L., Smolic, R., Vcev, A. ... Smolic, M. (2021). Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology, 12.. doi: 10.3389/fphar.2021.678546
Roguljic, Hrvoje, et al. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology, vol. 12, 2021. https://doi.org/10.3389/fphar.2021.678546
Roguljic, Hrvoje, Vjera Nincevic, Kristina Bojanic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, Dragan Primorac, Andrijana Vceva, George Y. Wu and Martina Smolic. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology 12 (2021). https://doi.org/10.3389/fphar.2021.678546
Roguljic, H., et al. (2021) 'Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update', Frontiers in Pharmacology, 12. doi: 10.3389/fphar.2021.678546
Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, and sur.. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology [Internet]. 2021 [cited 2024 November 26];12. doi: 10.3389/fphar.2021.678546
H. Roguljic, et al., "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update", Frontiers in Pharmacology, vol. 12, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:396498. [Accessed: 26 November 2024]